Business context and reporting period
Exponent, Inc. is an engineering and scientific consulting firm. The supplied filing is a Form 10-Q for the quarter ended October 2, 2020—not 2019 Q3 as indicated in the request metadata. Comparisons below are against the three and nine months ended September 27, 2019. Figures are unaudited; dollar amounts are in millions unless noted.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $98.7 | $101.5 | $296.7 | $307.1 |
| Revenue before reimbursements | $93.5 | $95.5 | $281.1 | $289.2 |
| Operating income | $20.4 | $23.2 | $65.5 | $63.8 |
| Net income | $18.1 | $19.6 | $60.7 | $63.3 |
| Diluted EPS | $0.34 | $0.36 | $1.14 | $1.17 |
| Operating cash flow | — | $62.4 | $52.3 | |
| Cash, cash equivalents and short-term investments | $207.7 at Oct. 2, 2020 | $231.6 at Jan. 3, 2020 |
- Q3 operating margin was 20.7% of reported revenue; EBITDA was $26.0 million, or 27.8% of revenue before reimbursements, versus 27.2% a year earlier. Nine-month EBITDA margin was 26.3%, down from 27.5%.
- Cash from operations increased year over year. Investing activities provided $30.9 million, mainly reflecting investment maturities and lower capital spending; financing used $82.2 million, including $40.0 million of share repurchases and $29.9 million of dividends and dividend equivalents.
- Current assets were $328.6 million and current liabilities $96.4 million. The company reported no debt; operating lease liabilities totaled $20.9 million. Management said available liquidity and operating cash flow should cover requirements for at least 12 months.
- Quarterly dividend declared after period-end was $0.19 per share, payable December 18, 2020, subject to board oversight. Repurchase authorization remaining at quarter-end was $75.5 million; no shares were repurchased during Q3.
Material changes versus comparable periods
- Q3 revenue declined 2.8% and revenue before reimbursements declined 2.1% year over year. Nine-month revenue fell 3.4%.
- Engineering and Other Scientific revenue fell 4.6% in Q3 and 5.6% for the nine months. Environmental and Health revenue rose 5.1% and 6.1%, respectively.
- Q3 operating income declined 12.0% and net income fell 7.9%; nine-month operating income rose 2.8% while net income decreased 4.1%. Q3 diluted EPS fell from $0.36 to $0.34.
- Q3 billable hours fell 9% and utilization decreased to 66% from 72%; technical FTEs declined 1%. Nine-month cash from operations rose to $62.4 million from $52.3 million.
- Nine-month other income fell to $4.6 million from $13.6 million, largely reflecting deferred-compensation investment performance and lower interest income. Nine-month effective tax rate fell to 13.4% from 18.1%, mainly due to higher excess tax benefits on stock awards; in Q3, the rate rose to 26.6% from 22.1% as those benefits were zero versus $1.7 million a year earlier.
Outlook, risks and unusual items
- For the first three weeks of Q4, management reported net revenues approximately 5%–7% below the comparable prior-year period. It cautioned that continuing uncertainty and changing COVID-19 restrictions could further reduce near-term revenue; no full-quarter or annual numerical guidance was provided.
- COVID-19 restrictions delayed litigation support work, field inspections, laboratory testing and human participant studies. Management cited strength in utility integrity advisory services and chemical regulation and food safety work, including services related to coronavirus disinfectants.
- The company recorded an approximately $1.3 million COVID-related addition to its receivables allowance; total allowance rose to $5.8 million from $4.3 million at fiscal year-end. Management identified client credit and collections as ongoing uncertainties.
- Deferred-compensation plan market movements affect both compensation expense and miscellaneous income. Q3 included a $3.2 million increase in plan asset value with a corresponding income/expense effect; nine-month plan asset value decreased $0.4 million, compared with an $8.4 million increase in the prior-year period.
- Key risks include pandemic duration and economic effects, project timing and limited backlog visibility, client payment capacity, hiring and retention, competition, litigation exposure, and currency and data-security risks. The company reported no material legal proceedings and no material change in contractual obligations.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the supplied filing covers Q3 2020, despite the request metadata specifying 2019 Q3.
- Track whether project delays, utilization and billable hours recover, and compare subsequent actual revenue with the early-Q4 decline disclosed here.
- Monitor receivables, allowance adequacy and collections as COVID-related economic uncertainty evolves.
- Separate underlying operating trends from deferred-compensation mark-to-market effects and variable stock-based tax benefits.
- Assess cash generation against dividends, repurchases, capital expenditures and lease obligations; future dividends and repurchases are not assured.